Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1655813 | 0.97 | — | — | |
| SCHEMBL25682240 | 0.87 | MCL1 (0.41) | — | |
| SCHEMBL4075839 | 0.77 | NPC1 (0.37) | — | |
| SCHEMBL499584 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL27773167 | 0.77 | — | — | |
| SCHEMBL13194213 | 0.76 | — | — | |
| SCHEMBL10050997 | 0.76 | — | — | |
| SCHEMBL5909428 | 0.76 | MCL1 (0.55) | — | |
| SCHEMBL18519236 | 0.74 | MEN1 (0.61) | — | |
| SCHEMBL6655925 | 0.73 | ALDH1A1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3678654-B1 | PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES | MERCK SHARP & DOHME LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-12016914-B2 | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof | MERCK SHARP & DOHME LLC (US) | 2024-06-25 | — | — | US | disclosed |
| US-11992521-B2 | Methods for producing Streptococcus pneumoniae capsular polysaccharide carrier protein conjugates | MERCK SHARP & DOHME LLC (US) | 2024-05-28 | — | — | US | disclosed |
| US-20240139303-A1 | ENHANCING IMMUNOGENICITY OF STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES | MERCK SHARP & DOHME LLC (US) | 2024-05-02 | — | — | US | disclosed |
| US-11964023-B2 | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates | MERCK SHARP & DOHME LLC (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240108711-A1 | COMPOSITIONS COMPRISING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240108742-A1 | METHODS FOR PRODUCTION OF CAPSULAR POLYSACCHARIDE PROTEIN CONJUGATES FROM STREPTOCOCCUS PNEUMONIAE SEROTYPE 19F | MERCK SHARP & DOHME LLC (US) | 2024-04-04 | — | — | US | disclosed |
| US-11896656-B2 | Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide | MERCK SHARP & DOHME LLC (US) | 2024-02-13 | — | — | US | disclosed |
| US-11883502-B2 | Methods for production of capsular polysaccharide protein conjugates from Streptococcus pneumoniae serotype 19F | MERCK SHARP & DOHME LLC (US) | 2024-01-30 | — | — | US | disclosed |
| US-11850278-B2 | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof | MERCK SHARP & DOHME LLC (US) | 2023-12-26 | — | — | US | disclosed |
| EP-2382986-A2 | VACCINE AGAINST STREPTOCOCCUS PNEUMONIAE | GlaxoSmithKline Biologicals s.a. (BE) | 2011-11-02 | — | — | EP | disclosed |
| US-20110195086-A1 | 15-VALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE VACCINE COMPOSITION | MERCK SHARP & DOHME LLC | 2011-08-11 | — | — | US | disclosed |
| US-20100239604-A1 | VACCINE COMPRISING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CONJUGATES | GLAXOSMITHKLINE BIOLOGICALS. S.A. | 2010-09-23 | — | — | US | disclosed |
| US-20100209450-A1 | VACCINE COMPRISING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CONJUGATES | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2010-08-19 | — | — | US | disclosed |
| US-20100183662-A1 | VACCINE COMPRISING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CONJUGATES | GLAXOSMTHKLINE BIOLOGICALS, S.A. (BE) | 2010-07-22 | — | — | US | disclosed |
| US-20100074922-A1 | Pneumococcal polysaccharide conjugate vaccine | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2010-03-25 | — | — | US | disclosed |
| US-20090162394-A1 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2009-06-25 | — | — | US | disclosed |
| US-20090017072-A1 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2009-01-15 | — | — | US | disclosed |
| US-20090017059-A1 | Complex of serotype to bacteria toxin such as tetanus, diphtheria, pertussis, cytolysin | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2009-01-15 | — | — | US | disclosed |
| US-20090010959-A1 | Pneumococcal Polysaccharide Conjugate Vaccine | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2009-01-08 | — | — | US | disclosed |